Brokers Issue Forecasts for Nevro Corp’s Q3 2019 Earnings (NVRO)

Nevro Corp (NYSE:NVRO) – Stock analysts at William Blair issued their Q3 2019 earnings estimates for shares of Nevro in a note issued to investors on Tuesday. William Blair analyst M. Kaczor anticipates that the medical equipment provider will post earnings of ($0.06) per share for the quarter.

Other analysts have also issued reports about the stock. BidaskClub lowered shares of Nevro from a “hold” rating to a “sell” rating in a research report on Saturday, October 28th. TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. BMO Capital Markets reiterated a “buy” rating and issued a $100.00 price target on shares of Nevro in a research report on Thursday, December 14th. Northland Securities reiterated a “buy” rating and issued a $96.00 price target on shares of Nevro in a research report on Tuesday, November 7th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $110.00 price target (up from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $99.25.

Nevro (NYSE NVRO) traded down $0.49 during mid-day trading on Wednesday, hitting $77.40. 351,848 shares of the stock traded hands, compared to its average volume of 528,783. The firm has a market capitalization of $2,290.00, a price-to-earnings ratio of -53.38 and a beta of -0.83. Nevro has a twelve month low of $65.00 and a twelve month high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59.

Nevro (NYSE:NVRO) last issued its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 7.57% and a negative return on equity of 10.30%. The company had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same period in the prior year, the business posted ($0.14) earnings per share. The firm’s revenue for the quarter was up 35.0% compared to the same quarter last year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Frontier Capital Management Co. LLC boosted its position in Nevro by 16.5% during the fourth quarter. Frontier Capital Management Co. LLC now owns 887,402 shares of the medical equipment provider’s stock worth $61,266,000 after acquiring an additional 125,632 shares during the last quarter. Hamilton Lane Advisors LLC boosted its position in Nevro by 600.3% during the fourth quarter. Hamilton Lane Advisors LLC now owns 23,221 shares of the medical equipment provider’s stock worth $1,603,000 after acquiring an additional 19,905 shares during the last quarter. Bank of Montreal Can boosted its position in Nevro by 73.3% during the fourth quarter. Bank of Montreal Can now owns 26,234 shares of the medical equipment provider’s stock worth $1,811,000 after acquiring an additional 11,095 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Nevro during the third quarter worth approximately $636,000. Finally, Point72 Asset Management L.P. boosted its position in Nevro by 35.4% during the third quarter. Point72 Asset Management L.P. now owns 542,952 shares of the medical equipment provider’s stock worth $49,343,000 after acquiring an additional 141,963 shares during the last quarter.

In other news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 12.10% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/01/18/brokers-issue-forecasts-for-nevro-corps-q3-2019-earnings-nvro.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit